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B lymphocytes proliferate and differentiate in response to various lymphokines
(1, 2) . Progress has been made recently in the understanding of the mechanisms
leading to a coordinated immune response due to the availability of some of these
lymphokines in recombinant form . IL-2 (3), IFN-y and a (4-6), TNRa/ß (7, 8),
a low molecular weight B cell growth factor (LMW BCGF)' (9) and a not yet
molecularly defined high molecular weight BCGF (10, 11) have been shown to in-
duce proliferationofactivated normal human B cells . IL-2 (12), IL-5 (13), BSF2/ß2-
IFN/IL-6 (14-16) have been shown to induce B cell differentiation . It has been re-
cently demonstrated that mouse (17) andhuman IL-4 (18) have pleiotropic effects .
IL-4 induces proliferation of activated B cells (19, 20) and T cells (21, 22) and the
expression of the low affinity receptor for IgE (FccR2/CD23) (23, 24) on resting B
cells (25, 26) as well as on certain B cell lines (27) . IL-4 was also found to play a
central role in the regulation of IgE production in mouse (28) and in human (29),
possibly throughthe release ofIgEbinding factors (30) . IL-4 was also able to induce
IgG and IgMproduction by Staphylococcus aureus strain Cowan-activated B cells (SAC)
(31) . However, little work has yet dealt with the effect ofcombinations of lymphokines
on the various stages of B cell maturation . We have reported that IFN-y was en-
hancing the IL-4-induced proliferation of preactivated B cells, whereas it inhibited
the IL-4-induced Fc&R2/CD23 expression (20, 25), as well as IgE production (29) .
IFN-y was also found to enhance IL-2-mediated B cell differentiation (32, 33) . Simi-
larly, partially purified LMW BCGF has been shown to act in concert with IL-4
(20) and IL-2 (34, 35) to promote B cell proliferation.
It was the purpose of this study to investigate the effects of combinations of IL-2
and IL-4 on human B cell proliferation and differentiation . The data indicate that
the level ofmaximal response of preactivated B cells for growth and differentiation
is higher with IL-2 than with IL-4 and that IL-4 antagonizesthe proliferative effect
of IL-2 without altering IL-2-induced differentiation .
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Materials and Methods
Factors.
￿
Purified IFN-y (y4A, 10 7 U/mg) and purified IL-2 (3 x 106 U/mg) were pur-
chased fromAmgen Biologicals(Thousands Oaks, CA) . 1U ofIL-2 is defined as the amount
Address correspondence to Thierry Defiance,UNICET, 27 chemin des Peupliers, B . P 11, 69572, Dardilly,
France .
1 Abbreviations used in thispaper: BCLL, chronic lymphocytic leukemia B cells; LMWBCGF, lowmo-
lecular weight B cell growth factor; PI, propidium iodide ; SAC, Staphylococcus aureus strain Cowan I .
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of IL-2 that induces 50% of maximal [3H]TdR incorporation by IL-2-dependent T cells in
culture. The optimal concentration of rIL-2 as determined in the B cell proliferation assay
using 1-d preactivated anti-IgM blasts was found to be within the range of 5 to 10 IU/ml.
Highly purified rIL-4 (from L 929 cells; 1.2 x 10' U/mg) was a kind gift ofDr. Arai (DNAX,
Palo Alto, CA) (36). 1 U of IL-4 is defined as the amount of IL-4 required to cause half-
maximal stimulation of tritiated thymidine ([3H]TdR) uptake by 5 x 103/200 Al T cells,
which were preactivated for 3 d with PHA and then extensively washed. Since preliminary
experiments had determined that optimal proliferation of anti-IgM blasts was reached with
a concentration ofpurified rIL-4 of500 U/ml, all preincubation experiments were performed
with 500 U/ml of rIL-4. A commercial preparation ofa LMW BCGF partially purified from
the culture supernatants of PHA-stimulated PBL was obtained from Cellular Products, Inc.
(Buffalo, NY) and will be referred to in the text as LMW BCGF.
Mitogens.
￿
Insolubilized rabbit anti-human IgM antibody was purchased from Bio-Rad
Laboratories (Richmond, CA). Formalinized SAC was purchased as Pansorbin from Cal-
biochem-Behring Corp. (La Jolla, CA).
Antibodies.
￿
The monoclonal and polyclonal antibodies used for phenotyping the B cell
preparations were purchased from the following manufacturers: Becton-Dickinson Mono-
clonal Center (Mountain View, CA): Leu 3 (CD4), Leu 5 b (CD2), Leu 7, Leu 11 (CD16),
Leu 12 (CD19), Leu M3 (CD14); Ortho Pharmaceutical Corp. (Raritan, NJ): OKT3 (CD3),
OKT4 (CD4), OKT8 (CD8), OKT11(CD2); Coulter Immunology (Hialeah, FL): BI (CD20),
M01 (CDll) and M02 (CD14); Behring AG (Marburg, Federal Republic of Germany):
F(ab')2 fragments anti-human Ig coupled to FITC; Grub (Vienna, Austria): FITC-con-
jugated F(ab')2 fragments of goat anti-mouse Ig used in the indirect immunofluorescence
assays. The neutralizing rabbit anti-IL-4 serum was raised in our laboratory and was pre-
pared as follows. Male rabbits were immunized subcutaneously and intramuscularly with
100 ug of Escherichia coli-derived rIL-4 in 1 ml CFA (Difco Laboratories, Detroit, MI). The
animals were boosted twice with rIL-4. Blood was collected 3 wk after the third immuniza-
tion and the antiserum was isolated. The Ig fraction was purified on protein A columns (Bio-
Rad Laboratories). This antiserum is specific for IL-4: it blocks IL-4-induced IgG/IgM produc-
tion from SAC blasts (31), IL-4-induced proliferation of T and B cells, and IL-4-induced
CD23 expression on the Burkitt lymphomacell line Jijoye (Chretien, I., A. van Kimmenade,
M . K. Pearce, J. Banchereau, J. S. Abrams, submitted for publication). The anti-IL-4 anti-
serum did not block the biological activities of IL-2 either on T cells (proliferation) or on
B cells (proliferation and differentiation). The biological activities of rIL-4 originating from
different sources (L929 cells, CHO cells, and E. colt) were equally blocked by the anti-IL-4
antiserum. A neutralizing anti-IFN-'P serum raised in the laboratory was used as control.
B Cell Preparations,
￿
B cells were isolated from tonsils. Mononuclear cells were separated
by standard Ficoll/Hypaque gradient method. B cells were obtained by twice rosetting with
aminoethylisothiouronium (AET Sigma Chemical Co., St. Louis, MO)-treated S RBC. The
B cell-enriched populations obtained were typically >95% surface Ig-positive, >957o BI
(CD20) antigen-positive. Less than 1 % of the cellsexpressed the T cell markers CD2, CD3,
CD4, and CD8, or the monocyte markers CD11 and CD14. Less than 1% of the cells reacted
with the NK cell markers Leu 7 and Leu 11. Purified B cells were then further separated
according to size using a discontinuous gradient of Percoll (Pharmacia Fine Chemicals, Upp-
sala, Sweden) consisting of four solutions (1.075, 1.070, 1 .060, and 1 .055 g/ml) sequentially
layered on top of each other (3 ml of each solution in a 15-ml centrifuge tube, No. 2095;
Falcon Labware, Oxnard, CA). 5 x 10' purified B cells were laid on top of the gradient
and centrifuged for 20 min at 550 g at 20'C. Resting B cells were recovered in the pellet,
below the solution of Percoll of the highest density (p > 1.075 g/ml).
Culture Conditions and Assays.
￿
Purified B cells were cultured in Iscove's medium enriched
with 50 ug/ml human transferrin, 0.5 17o BSA, 5 ug/ml bovine insulin, oleic, linoleic, and
palmitic acids (all from Sigma Chemical Co.), and 2% heat-inactivated FCS (Industrie Bi-
ologique Fran~aise, Genevilliers, France) as described by Yssel et al. (37) for proliferation
assays. For differentiation assays, complete RPMI 1640 medium (Flow Laboratories, Irvine,
CA) supplemented with selected heat-inactivated FCS, 2 mM glutamine, 100 U/ml peni-
cillin, 100 Ng/ml streptomycin (all from Flow Laboratories), 50 wg/ml gentamicin (Laboratorres
UNICET Levallois-Perret, France), and 2% Hepes was used.DEFRANCE ET AL.
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Proliferation Assay.
￿
B lymphocytes adjusted at 2 x 106 cells/ml in enriched Iscove's medium
described above were stimulated by insolubilized anti-IgM antibody (10 Rg/ml) for 24 h. After
activation, B cell blasts were harvested and centrifuged over Ficoll/Hypaque gradient to re-
move nonviable cells and anti-IgM beads. They were then resuspended at 106 cells/ml in en-
riched Iscove's medium and dispensed under a volume of 50 A1 into wells of microtiter trays.
Factors to be tested for their B cell growth-promoting activity were added to reach a final
volume of 100 pl. Cells were pulsed with [3H]TdR (1 pCi/well, sp act 25 Ci/mmol; CEA,
Saclay, France) during the last 16 h of the culture period. [3H]TdR uptake was measured
by standard liquid scintillation counting techniques after harvesting, using a scintillation
counter (LKB Instruments, Bromma, Sweden). The proliferative response of B cell blasts
was measured at different intervals from the beginning of culture (from day 2 to day 6). In
some experiments, B cell blasts generated after 1 d of preactivation with SAC (0.05%) were
also used.
Cell CycleAnalysis.
￿
The flow cytometric measurement oftotal DNA content was done using
three different techniques: a single staining method with propidium iodide (PI), a single staining
method using Hoechst 33 342 as described by Taylor (38), and a double-staining method
combining bromodeoxyuridine (BrdUrd), which is incorporated in place of thymidine in
DNA during S phase of the cell cycle, and PI, which stains double-stranded DNA. This tech-
nique was performed according to Dolbeare et al. (39), with some modifications as described
previously (20). DNA histograms, obtained after PI or Hoechst single staining, were ana-
lyzed using the mathematical model of Dean and Jett (40). Each DNA histogram was built
after acquisition of 2 x 104 cells.
Differentiation Assay.
￿
High density tonsillar B cells (p > 1 .075 g/ml) at 2 x 106 cells/ml in
complete RPMI 1640 medium (as described above) were stimulated for 2 d with SAC used
at a final concentration of 0.05%. To remove nonviable cells and SAC particles, activated
B cells were centrifuged (15 min, 550 g) on a gradient consisting of two overlaid solutions
of Percoll with densities of 1.077 g/ml and 1.055 g/ml. Viable B cell blasts were recovered
at the interface between the two solutions. B cell blasts resuspended in complete RPMI medium
were then dispensed (105 cells/well) into wells of flat-bottomed microtiter trays (Falcon Lab-
ware). Factors to be tested were added in appropriate volumes to reach a final culture volume
of 200 ul per well. Each culture point was performed in quadruplicate. Supernatants were
harvested 4 d after the onset of the second culture and were kept at -20'C until Ig levels
were determined by ELISA. In some experiments, SAC-activated B cell blasts were further
separated into CD25' (Tac') and CD25- (Tac- ) populations with the FAGS after indirect
immunofluorescence staining using an anti-CD25 mAb (BI 49.9 mAb; Immunotech, Marseille
Luminy, France) and FITC-conjugated F(ab')2 fragments of goat anti-mouse Igs (Grub).
The two populations were assayed for proliferation and differentiation using the culture con-
ditions described above.
Assay ofIg Production.
￿
The cumulative total Ig in the culture was determined by double
sandwich ELISA as described by Voller (41). Briefly, microtiter plates (Immunoplates; Nunc,
Roskilde, Denmark) were coated with 200 wl of appropriate dilutions of specific anti-IgG,
anti-IgM (Behring AG, Marburg, Federal Republic ofGermany) or anti-IgA (Biosys, Com-
piegne, France) in pH 9.6 carbonate buffer overnight at 4'C. After washing, 200-w1 serial
dilutions of IgG, IgA, and IgM standards (Behring) in PBS Tween 0.05% were added to
the respective plates as calibration curves. Dilutions of culture supernatants were added at
the same time. After 2 h at room temperature, the plates were washed, and 200 ul of diluted
specific alkaline phosphatase-conjugated anti-IgG, anti-IgM (Behring), or anti-IgA (Biosys)
was added. After 2 h at room temperature, plates were washed and 200 pl p-nitrophenylphos-
phate (Sigma Chemical Co.) in diethanolamine buffer was added. Plates were incubated at
370C, and OD were measured at 405 nm by using an Autoreader (MR 580; Dynatech Labora-
tories, Inc., Alexandria, VA). OD data were collected and were processed with an Apple IIe
computer. Concentrations of Ig in culture supernatants were expressed as nanograms per
milliliter.
Preculture Experiments.
￿
B cell blasts (generated after 24 h of stimulation with insolubilized
anti-IgM or SAC) or high density resting B cells were cultured for 24 h at a cell density of
2 x 106 cells/ml in complete RPMI 1640 medium alone or with rIL-4 (500 U/ml). After
preculturing, B cells were centrifuged (15 min, 550 g) on a Percoll solution of 1.055 g/ml.132 4
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Viable cells recovered in the pellet were then washed and tested for theircapacity to proliferate
in response to different factors. When resting B cells were used for preculture experiments,
the factors to be tested in the second culture period were used in costimulation with insolubi-
lized anti-IgM antibody (at a final concentration of 10 jig/ml). The proliferative response
was routinely measured 3 or 4 d afterthe onset of the second culture with a [3H]TdR pulse
during the last 16 h of culture.
Results
rIL-2-dependent B Cell Proliferation of Preactivated B Cells Is Inhibited by rIL-4.
￿
We
have demonstrated earlier that IL-4-induced B cell proliferation was enhanced by
semipurified LMW BCGF and IFN-1' (20). Since IL-2 displays B cell growth-
promoting activity and has also been demonstrated to act in cooperation with other
B cell growth factors (34, 35), we studied the proliferation of activated B cells in
response to combinations of rIL-4 and rIL-2. For this purpose, a two-step assay was
performed. Highly purified tonsillar B cells were first preactivated for 24 h with in-
solubilized anti-IgM antibody (10 wg/ml) or SAC, then recultured for an additional
period of 3 d with either purified rIL-4, purified rIL-2, or with a combination of
both lymphokines. B cell proliferation was monitored by [3H]TdR uptake. As il-
lustrated in Table I, at optimal concentration ofboth lymphokines (10 U/ml for rIL-
2; 500 U/ml for rIL-4) the levels of [3H]TdR incorporation obtained with rIL-2 were
significantly higher than thoseobtained with rIL-4. Surprisingly, when preactivated
B cells were cocultured with rIL-4 and rIL-2, B cell proliferation was lower than
that observed with rIL-2 alone and was in most cases comparable to the levels of
proliferation obtained with rIL-4 alone (Exps. 1, 2, 4, 5, Table I). In some experi-
ments (Exps. 3 and 6, Table I), addition of rIL-4 to rIL-2-stimulated cultures did
not reduce the levels of [3H]TdR uptake to these obtained with rIL-4 alone, al-
though the proliferative response to rIL-2 was significantly inhibited. It is also shown
(Table I, Exp. 6) that relatively low amounts of rIL-4 (20 U/ml) can significantly
reduce the growth-promoting effect of rIL-2, and that the inhibitory effect of rIL-4
on rIL-2-mediated proliferation is also observed when SAC is used instead of anti-
IgM antibody for preactivation ofB cells. In some experiments, (one of five, approx-
imately) the proliferation in response to rIL-4 was higher than the proliferation
TABLE I
rIL-4 Inhibits the rIL-2-mediated Proliferation of Preactivated B Cells
Exps. 1-5 were performed on anti-IgM blasts recovered after 1 d of preactivation. Exp. 6 was performed
on SAC blasts recovered after 1 d ofpreactivation. Each value represents the mean t SD of triplicate deter-
minations. rIL-2 was used at the final concentration of 10 U/ml. rIL-4 was used at the final concentration
of 500 U/ml (Exp. 1-4); 100 U/ml (Exp. 5) and 20 U/ml (Exp. 6).
Exp. 1 Exp. 2
[3H]TdR
Exp. 3
(cpm x
incorporation
Exp.
10 -3 t
4
SD)
Exp. 5 Exp. 6
0 0.6 ± 0.2 2.8 t 0.4 5.8 t 0.8 5.6 t 0.2 18.2 ± 1 .8 1 .5 t 0.3
rIL-4 11 .6 f 1 .0 13.2 t 0.2 11 .8 t 0.9 12.9 t 0.4 54.7 f 5.4 8 .1 t 0.1
rIL-2 31 .5 t 0.8 24.3 t 0.2 85.4 t 4.0 28 .3 ± 0.6 98.1 t 2.4 64.9 t 1 .7
rIL-2 t rIL-4 13.8 t 0.9 16.0 t 0.7 43.9 t 10.0 17 .9 t 1 .8 59 .9 t 3.6 32 .9 f 2 .5DURANCE ET AL.
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obtained in response to rIL-2, and the proliferative response to the combination
ofrIL-2 and rIL-4 was equal to that obtained in response to rIL-4 (not shownhere).
The cell cycle studies performed using thedouble-staining BrdUrd/PI, or the single-
staining systems (PI or Hoechst 33 342) confirmed the [3H]TdR uptake data. B cell
blasts generated after 2 d of preactivation with SAC were recultured for 3 d with
rIL-2 (10 U/ml), rIL-4 (500 U/ml), or rIL-2 + rIL-4. To prevent cycling cells from
returning to Go/Gt, colcemid (0.1 wg/ml) was added during the last 24 h of the cul-
ture. Data displayed in Table II show that rIL-4 significantly reduces the number
ofcellsentering into cycle in response to rIL-2. The inhibition ofthe rIL-2-mediated
B cell proliferation was a function of the concentration of rIL-4 used in the assay
(Fig. 1). Kinetics experiments(Fig. 2) demonstrated that the inhibitory effect of rIL-4
wasnot simply due to adelayedproliferative response to rIL-2, since inhibition could
be observed from day 3 up to day 6 after the onset of the culture. When [3H]TdR
uptake was measured at earlier time points (12, 24, and 48 h), it was consistently
observed that the peak of [3H]TdR uptake in response to rIL-2 was not precipitated
in the presence of rIL-4 and that rIL-4 could inhibit the growth promoting effect
of rIL-2 as early as 24 h after the onset of the culture (data not shown). To rule
out the possibility that the antagonizing activity of IL-4 could be mediated via a
non-B cell population, phenotypic analysis were performed on SAC blasts that were
recultured for 2 additional d with rIL-2 (10 U/ml), rIL-4 (500 U/ml) or rIL-2 plus
rIL-4. As illustrated in Fig. 3, immunofluorescence stainings performed with anti-
CD2 and anti-CD20 mAbs established that these three cell populations were com-
posed of >95% B cells, whereas T cells remained under detection levels. Taken to-
gether these data indicate that IL-4 can at least partially inhibit the proliferative
response of activated B cells to IL-2 and suggest that the antagonizing effect of IL-4
is exerted directly on B cells.
Effect ofPreculture with rIL-4 on theSubsequent Proliferative Response ofB Cells to rIL-2.
To furtherexplorethe inhibitory mechanismof IL-4 on IL-2-induced B cell prolifer-
ation, experiments were designed in which B cellswere firstpreincubated with rIL-4
for 24 h before culturing with rIL-2. In the first set of experiments, B cell blasts
TABLE II
rIL-4 Reduces the Number of B Cells Entering into Cycle
Upon rIL-2 Stimulation
B cells blasts generated after 2 d of preactivation with SAC were further recul-
tured for 3 d with rIL-4 (500 U/ml); rIL-2 (10 U/ml); or rIL-4 + rIL-2 . Col-
cemid (0.1 ug/ml) was added during the last 24 h of the culture to block cells
in G2/M. In Exp. 1 and 4, DNA staining was performed using BrdUrd and
PI. In Exp. 3, DNA staining was performed with Hoechst 33 342. In Exp. 2,
DNA staining was performed with PI.
Exp. rIL-4
Cells in S and G2/M
rIL-2 rIL-4 + rIL-2
TO 170 %
1 33 41 35
2 23 45 24
3 11 24 13
4 19 25 191326
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FIGURE 1 . The inhibitory
effect of rIL-4 is a function of
rIL-4 concentration . 1-d preac-
tivated anti-IgM blasts (5 x
104 blasts/well) were recultured
for 3 d with purified rIL-2 (10
U/ml) with or without vari-
ous concentrations of purified
rIL-4 . Thehistogram bars rep-
resent the proliferative response
of anti-IgM blasts to rIL-4
alone, the curve represents the
proliferative response of the
blasts cocultured with rIL-2and
rIL-4 . Representative of three
experiments .
generated after 24 h of activation with SAC were further incubated for 24 h with
or without rIL-4 (500 U/ml) and then recultured for 72 h with rIL-2 . The results
of these experiments, illustrated in Fig . 4, indicate that pretreatment ofSAC-activated
B cellswith rIL-4 decreases their subsequent proliferation in response to rIL-2. Simi-
larly, B cell blasts preactivated with anti-IgM, which were incubated with rIL-4 for
24 h, displayed a decreased responsiveness to the growth-promoting effect of rIL-2
compared with control blasts incubatedwith medium (datanot shown) . In a second
set of experiments, high density tonsillar B cells (p > 1.075 g/ml) were precultured
withmedium aloneor with rIL-4(500 U/ml) for 24h andthen assayed for prolifera-
tion in response to rIL-2, rIL-4, or rIL-2 plus rIL-4 in costimulation with insolubi-
lized anti-IgM antibody . The data illustrated in Fig . 5 A show that pretreatment
of restingB cells with rIL-4 does not alter their capacity to proliferate subsequently
in response to rIL-2 and anti-IgM antibody. Comparable resultswere obtainedwhen
the period of incubation with rIL-4 was prolonged to 48 h (data not shown) . The
FIGURE 2 . rIL-4 does not
modify the time kinetics of the
proliferative response to rIL-2 .
1-d activated anti-IgM blasts
were recultured for different
lengths of time in the presence
ofrIL-4 (500 U/ml) (®), rIL-2
(10 U/ml) (IM), or rIL-4 plus
rIL-2 (®). The [3H]TdR pulse
was performed during the last
16 hofthe culture period. Rep-
resentative of three experi-
ments.IL-2
t
IL-4
2so
m
a
2+0
10'
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ated after48 hofactivation with SAC
were recultured for 48 h with rIL-4
(500 U/ml), rIL-2 (10 U/ml), or rIL-4
plus rIL-2 and stained with a FITC
conjugated panT cell marker (anti-
CD2 mAb) oraFITC conjugated pan-
B cell marker (anti-CD20 mAb). The
negative control was performed with
anonrelated mAbof thesame isotype.
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addition of HL-4 together with HL-2 and anti-IgM antibody to rIL-4-pretreated
cells during the second culture reduces the rIL-2-mediated proliferation to the level
of proliferation induced by HL-4 itself (Fig. 5 B). This was observed as well for the
control samplesthat had been pretreated with medium during the firstculture period
FIGURE 4.
￿
Preculture of 1 d
preactivated SAC blasts with
rIL-4reducestheircapacity to
subsequently proliferate in re-
sponse to rIL-2. B cell blasts
generated after 24 h of activa-
tion with SAC were submitted
to a further incubation with
rIL-4 (500 U/ml) (*) or me-
dium ([D) during 24 h before
thesecond cultureperformedin
thepresence of increasing con-
centrationt of rIL-2. Prolifera-
tive response wasmeasured 4d
after the onset of the second
culture. With [3H]TdR added
16 h before harvesting. Repre
0
￿
is
￿
20
￿
sentative of four experiments.
L 2 (U/mi )
FIGURE 3.
￿
Phenotypic analysis of B
cell blasts recultured with rIL-2, HL-4,
103 ￿io'
￿
or rIL-2 plus
-ITA B cell blasts gener -,-
i0' 1041328
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FIGURE 5.
￿
Preculture of resting B cells
with rIL-4 does not alter theircapacity to
proliferate in response to rIL-2plus anti-
IgM. RestingB cells recoveredin thehigh
density fraction (p > 1.075 g/ml)aftercen-
trifugation on Percoll gradients were first
incubatedwith medium (EI) or rIL-4(500
U/ml), (*)for24 h. Viable cells were then
recoveredandassayed forproliferation in
10
￿
thepresence ofincreasing concentrations
ofrIL-2and insolubilized anti-IgM anti-
body (10I+g/ml). (A) A comparison of the
proliferative responses of the IL-4 pre-
treatedcells andcontrolcultures. (B)rIL-4
pretreated cells were furtherrecultured ei-
ther with rIL-2 alone plus anti-IgM ([D)
or with thecombination of rIL-2plus rIL-
4 (500 U/ml)and anti-IgM (+), allthree
reagents being added at the onset of the
second culture. Proliferative response was
measured4d aftertheonsetofthesecond
culture, [3H]TdRbeingadded 16 hbefore
harvesting. Representative of four ex-
periments.
(data not shown). These data suggest that IL-4 can affect the capacity of B cells to
proliferate in response to IL-2 only when thesecells have received an activation signal
in vitro.
rIL-4 Does Not InhibitrIL-2-induced B Cell Differentiation.
￿
Since IL-4 can drive ac-
tivated B cells to differentiate and produceIgG and IgM(31),we next studiedwhether
IL-4 inhibited the IL-2-mediated proliferation of activatedB cellsby enhancing their
differentiation. To test this hypothesis, B cell blasts generated from high densityton-
sillar B cells after 2 d of activation with SAC were recultured with rIL-4, rIL-2,
or the combination of both lymphokines at optimal and suboptimal concentrations.
B cell differentiation was monitored by measurement of Ig content (IgG, IgA, and
IgM) in the culture supernatants 4 d after the onset of culture. Data illustrated in
Table III show that, whatever the concentration of rIL-4 used in combination with
rIL-2, no inhibition of rIL-2-mediated IgG production is observed. At optimal con-w a
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centration of rIL-2 (10 U/ml), rIL-2-induced IgGproduction is not affected by rIL-4,
whereas at suboptimal concentrations of rIL-2 (0.3 and 1.25 U/ml), the effects of
rIL-4 and rIL-2 on IgG production are roughly additive. Similar results were ob-
tained with the production of IgM (data not shown) . It is noteworthy that rIL-2-
mediated IgA production is not suppressed by rIL-4, which by itself induces only
avery weak IgA production. To further explore the apparently contradictory effects
ofIL-4 on IL-2-mediated proliferation and IL-2-mediateddifferentiation, B cell blasts
recovered after 2 d of preactivation with SAC were sorted according to the expres-
sion of CD25. CD25' and CD25- B cells were then assayed for proliferation and
differentiation in response to optimal concentrations of rIL-4, rIL-2, or rIL-2 plus
rIL-4. Data illustrated in Table IV demonstrate that the CD25+ population
proliferates anddifferentiates in response to both rIL-2 and rIL-4. In addition, rIL-
4 was found to inhibit the proliferation of CD25+ B cells in response to rIL-2
without affecting rIL-2-induced differentiation. The CD25 - B cells did not
proliferate nor did they differentiatein response to rIL-4, rIL-2, or to the combina-
tion ofboth lymphokines (datanot shown). Takentogether, these data demonstrate
that IL-4 does not inhibit IL-2-mediated B cell proliferation through an enhance-
ment of B cell differentiation.
TheInhibitory Effect ofrIL-4 Is Blockedby a NeutralizingAnti-IL-4Antiserum.
￿
To rule
out the possibility that theinhibitory effect of rIL-4 could be mediated by contaminants
of the rIL-4 preparations, anti-IgM-activated B cells blasts were recultured for 4
d with rIL-2 (10 U/ml), rIL-4 (20 U/ml), rIL-2 plus rIL-4, or rIL-2 plus rIL-4 in
the presence of a 1/500 dilution of a neutralizing rabbit polyclonal anti-IL-4 anti-
serum (Chrdtien, L, et al., submitted for publication). A neutralizing rabbit anti-
IFN-y antiserum was used as control and added at the same dilution to cultures
stimulated with rIL-2 and rIL-4. Additionally, to determine the minimum period
ofcontact required for rIL-4 to develop its inhibitory effect, theanti-IL-4 antiserum
was added at different time points during the culture (at the onset of the culture,
and 7, 16, 24, or 40 h after the onset of the culture). The results illustrated in Fig.
6 represent the proliferative response of 1-d preactivated anti-IgM blasts stimulated
with rIL-2 plus rIL-4 in the presence of the anti-IL-4 antiserum or of the control
TABLE IV
Effect of the Combined Action of rIL-2 and rIL-4 on the Proliferation
and Differentiation of CD25+ B Cell Blasts
B cell blasts recovered after 2 d of activation of high density tonsillar B cells
with SAC were positively sorted according to the expression ofCD25. Prolifer-
ation of CD25 ` blasts was determined after 72 h of culture, and IgM produc-
tion was evaluated after 96 h of culture.
' Purified rIL-2 was used at 10 U/ml.
$ Purified rIL-4 was used at 500 U/ml.
[3H]TdR
cpm x
uptake
10 -3
IgM production
nglml x 10 - z
Medium 0 .5 f 0.07 1 .4 t 0.08
rIL-2' 59 .5 ± 0.1 14.9 ± 1 .0
rIL-41 9 .9 t 0 .6 7.6 t 0.4
rIL-4 + rIL-2 14.6 t 0 .4 14.4 t 0.8U
100000
80000
60000
40000
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FIGURE6.
￿
Effect ofdelayed ad-
dition of anti-IL-4neutralizing
serum to Bcell blasts cocultured
with rIL-4 and rIL-2. B cell
blasts generated after 1 d of
preactivation with insolubilized
anti-IgM were recultured with
HL-2 (10 U/ml), HL-4 (20
U/ml), HL-2 + HL-4, HL-2 +
HL-4 + anti-IL-4 (1/500) or
HL-2 + HL-4 + controlserum
(1/500). Anti-IL-4neutralizing
antiserum (p)or control anti-
serum (/) (anti-IFN-y anti-
serum) were addedat different
time points (at the onset of the
cultureor 7, 16, 24,or 40 hafter
the onset of the culture). The
proliferative response was mea-
sured after 4 d of culture,
[3H]TdR beingadded 16 h be-
fore harvesting. The [3H]Thd
uptake levels in response to
HL-2, HL-4, HL-2 plus HL-4
in the absence of antiserum
were,respectively: 106 t 4.0 x
103 cpm (0); 44 ± 4.0 x 103
cpm (A) and 62 t 2.0 x 103
cpm (O). Background
[3H]TdR uptake of anti-IgM
blasts cultured in medium alone
was: 6 f 0.5 x 103 cpm. Rep-
resentative of three
experiments.
antiserum. In the absence of antibody the [3H]TdR uptake in cultures of anti-IgM
blasts stimulated with rIL-4, rIL-2, or rIL-2 plus rIL-4 were, respectively: 44 ±
4.0 x 103 cpm, 106 t 4.0 x 103 cpm, and 62 t 2.0 x 103 cpm. When anti-IL-4
antiserum is added at the onset of the culture or 7 h after the onset of the culture,
the inhibitory effect of rIL-4 is totally blocked (levels of [3H]TdR uptake being
respectively, 90 and 98% of the level of [3H]TdR uptake induced by rIL-2 alone).
After 24 h of culture, addition of anti-IL-4 antiserum no longer blocks the inhibi-
tory effect of rIL-4. The presence of thecontrolantiserumdidnot affect rIL-4-mediated
inhibition of rIL-2-dependent B cell proliferation, whatever the time of itsaddition.
These data demonstrate that the inhibition observed with rIL-4 is not due to con-
taminants and that rIL-4 needs to be present for more than 24 h to fully deliver
its antagonizing effect.
Discussion
In this report, we have studied the proliferation and differentiation ofpreactivated
tonsillar human B cells in response to combinations of purified rIL-2 and rIL-4.
With the majority of the tonsillar B cell preparations, it was found that the maximal
proliferative response was higher with rIL-2 than with rIL-4 provided that these
factors were both used at optimal concentration. It was repeatedly observed that1332
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combinations of rIL-2 and rIL-4 resulted in proliferation that was lower than that
observed with rIL-2 alone and often equivalent to that observed with rIL-4. rIL-4
reduced the levels of [3H]TdR uptake (Table 1) induced by rIL-2 as well as the
number of cells cycling in response to rIL-2 (Table II). The antagonizing effect of
rIL-4 was a function of its concentration, and relatively low amounts of rIL-4 (12.5
U/ml) were sufficient to provide nearly maximum inhibition. Two lines of evidence
demonstrated that the inhibitory effects of rIL-4 could not be due to contaminants:
first, highly purified rIL-4 was used in all the experiments; second, the inhibitory
effect of rIL-4 could be totally reversed by a neutralizing polyclonal anti-IL-4 an-
tiserum. The inhibitory effect of rIL-4 was not due to a delayed response to rIL-2,
since the inhibition of [3H]TdR incorporation was observed from day 3 to 6. As
shownby phenotypic analysis with anti-CD2 and anti-CD20mAbs, the cell popula-
tions cultured with rIL-2, rIL-4, or rIL-4 plus rIL-2 were composed of >95% B
cells, whereas T cells andmonocytes remained belowthe levels ofdetection. There-
fore, it is unlikely that the growth inhibitory effect of IL-4 could be mediated via
a non-B cell population.
Treatment of anti-IgM as well as SAC preactivated B cells with rIL-4 for 24 h
significantly reduced their subsequent proliferation in response to rIL-2. Delayed
addition of the neutralizing anti-IL-4 antiserum to anti-IgM blasts cultured with
rIL-4 andrIL-2 established that the inhibitory effect ofrIL-4 on rIL-2-induced prolifer-
ation required cells to be in contact with rIL-4 for at least 24 h. This also corre-
sponds to the minimum length of time necessary for rIL-4 to display B cell growth
factor activity (20). In contrast, resting B cells pretreated with rIL-4 were still able
to fully respond to the growth-promoting activity ofrIL-2 in combination with anti-
IgM antibody. Nevertheless, readdition of rIL-4 together with rIL-2 and anti-IgM
antibody in thesecond culture period could still blockthe rIL-2-mediated prolifera-
tive response of these cells. These findings suggest that in vitro activation of B cells
with anti-IgM antibody or SAC before treatment with rIL-4 or together with rIL-4
is necessary for development of the inhibitory effect of rIL-4.
Experiments performed on SAC blasts demonstrated that rIL-4 did not suppress
rIL-2-induced Ig synthesis. rIL-4 did not significantlypotentiate Ig production in-
duced by rIL-2 (used at optimal concentration), therefore suggesting that the an-
tagonistic activity of rIL-4 on B cell proliferation induced by IL-2 was not due to
an enhancingeffect ofrIL-4 on rIL-2-mediated differentiation. However, the possi-
bility remained that the apparently unchanged levels of Ig production detected in
the rIL-2 plus rIL-4-stimulated cultures compared with the rIL-2-stimulated cul-
tureswas in fact reflecting the sumof rIL-4-induced Ig secretionand reduced rIL-2-
mediated Ig secretion. This hypothesis was ruled out by the IgA results (Table III),
which demonstratethat rIL-4 (which does not induce significant production of IgA
by itself) does not suppress rIL-2-mediated IgA production.
In view of the fact that IL-4 can cooperate with IFN-y and LMW BCGF for B
cell proliferation (20) and with IL-2 for T cell proliferation (22), the counteracting
effect of IL-4 on the B cell growth-promoting activity of IL-2 was an unexpected
finding. However, thereis nowgrowingevidence that IL-4 candelivernegative signals
to variouscell types. Indeed, it has been demonstrated that IL-4 suppresses the gener-
ation of LAK cells from PBL by IL-2 (42, 43). Moreover, IL-4 has been shown to
inhibit the factor-dependent growth of pre-B cells from bone marrow precursorsDEFRANCE ET AL.
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(44). In addition, ourfinding that IL-4 antagonizes IL-2-dependent growth of acti-
vated normal B cells is in line with the recent data obtained with chronic lympho-
cyticleukemia B cells(B-CLL), whose IL-2-dependent proliferation is totally blocked
by IL-4 (45). Our data thus indicate that the IL-4-mediated inhibition of IL-2-
dependent growth of B-CLL cellsis not merely due to the transformed state ofthese
cells. This suggests that B-CLL cells might represent the malignant counterpart of
the normal B cell subset sensitive to the antagonizing activity of IL-4.
The contrasting effects ofIL-4 on IL-2-mediated proliferation and differentiation
of preactivated human B cells suggest that these two IL-2-dependent events may
be dissociated. Whether this dissociation is linked to the existence of two different
B cell subsets, onedifferentiating andone proliferating in response to IL-2, remains
to be determined. However, in line with this hypothesis, there are now reports that
tend to support the notion that activated B cells can be separated according to their
capacity to proliferate or differentiatein response to T cell factors. It hasbeen shown
that the Bcell subset that proliferates in response to SAC is different from that which
differentiates in response to SAC and irradiated T cells, and that these two popula-
tions canbe separated by theirabilityor inabilityto form rosettes with mouseerythro-
cytes (46). Moreover, Nakagawa et al. (47) recently demonstrated that SAC-activated
B cell blasts can be divided into subsets that either differentiate or proliferate in
response to IL-2. It is thus tempting to speculate that the subpopulation prolifer-
ating in response to IL-2 is the target of the IL-4 inhibitory effects, whereas the
subpopulation differentiating in response to IL-2 is not affected by IL-4. It is likely
that theB cell subpopulations differentiatingin response to IL-2 andIL-4 maylargely
overlap, since the differentiative activities of both lymphokines used at optimal con-
centration are not additive, whereas they are roughly additive at suboptimal con-
centrations. In a first attempt to separate IL-2- and IL-4-responsive populations,
we sorted out CD25+ and CD25 - B cells from a total population of SAC-activated
blasts. It was found that B cells that did not express CD25 could not proliferate or
differentiate in response to rIL-2 or rIL-4. Thus, cells proliferating and differen-
tiating in response to rIL-2 or rIL-4 were included within the CD25 + subset. These
experiments also confirmed, at the level of a B cell subpopulation selected on the
expression of the IL-2 receptor, that rIL-4 can antagonize rIL-2-mediated B cell
growth without affecting rIL-2-induced Ig production. Presently, we can only spec-
ulate on the nature of the mechanism involved in the inhibitory activity of IL-4.
An IL-4-mediated downregulation of the expression of the IL-2 receptor hetero-
dimercould be a possible explanation. Binding experiments arepresently beingper-
formed to challenge this hypothesis.
The data presented in this report demonstrate that, in addition to its stimulatory
effects on theimmune response, IL-4 delivers inhibitory signalsto Bcells. This finding
adds further complexity to the understanding of the sequence of events that affect
a B cell once it has encountered its specific antigen.
Summary
The combined effect of IL-4 and IL-2 on proliferation of anti-IgM antibody or
Staphylococcus aureus strain Cowan I (SAC)-preactivated B cells was investigated.
It wasobserved that in most cases, rIL-2 used at optimalconcentration induced higher
levels of tritiated thymidine ([3H]TdR) uptake than rIL-4 used at optimal concen-1334
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tration. When rIL-4 and rIL-2 were added together, it was repeatedly found that
B cell proliferation induced by rIL-2 was significantly reduced and was, in most cases,
comparable with the proliferation induced by rIL-4 alone. Cell cycle studies demon-
strated that rIL-4 significantly reduced the number of cells entering S and G2/M
phases of the cell cycle upon rIL-2 stimulation. B cell blasts preincubated for 24
or 48 h with rIL-4 displayed a reduced proliferation in response to rIL-2. In con-
trast, preculture of resting B cells with rIL-4 did not impair their subsequent prolifer-
ation in response to rIL-2 plus insolubilized anti-IgM antibody. This suggests that
rIL-4 can only exert its inhibitory effect once B cells have received an activation
signal. The differentiative activity of rIL-2 measured on B cell blasts preactivated
for 2 d with SAC was not altered by rIL-4, which suggests that rIL-4 did not exert
its inhibitory activity on rIL-2-induced B cell proliferation by enhancing rIL-2-
mediated differentiation. Delayed addition of a neutralizing anti-IL-4 antiserum
demonstrated that a period of contact of at least 24 h between IL-4 and B cell blasts
was necessary for the development of the antagonistic effect of IL-4 on IL-2-mediated
growth of activated B cells. These data demonstrate that IL-4 antagonizes the B
cell growth-promoting effect of IL-2 without affecting the differentiation of preacti-
vated B cells in response to IL-2.
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